GlassScriptPhysician profile
David Olshan
NPI 1952899825
$28,745.23
in general payments reported to CMS, 2019-2025
11 companies · $18K in 2025
The $18K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $151 · 2022: $797 · 2023: $2,725 · 2024: $7,004 · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $18K · Travel and Lodging: $6,102 · Food and Beverage: $3,618 · Education: $577.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $17,500.00 |
| Travel and Lodging | $6,101.98 |
| Food and Beverage | $3,618.38 |
| Education | $576.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $9,818.00 | 2022-2025 | Emblem Mri S-Icd, Farapulse, General - Therapies |
| Medtronic, INC. | $9,580.48 | 2021-2025 | Azure Xt Dr Mri Surescan, Linq II |
| Biotronik INC. | $8,336.83 | 2021-2025 | Acticor 7 Vr-T Dx, Biomonitor, Rivacor 7 Dr-T |
| Biosense Webster, INC. | $457.11 | 2025 | Carto 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $189.98 | 2022-2023 | Jardiance |
| Novo Nordisk INC | $118.02 | 2022 | |
| Chiesi USA, INC. | $82.97 | 2022-2025 | Kengreal |
| Astrazeneca Pharmaceuticals LP | $43.08 | 2023 | Lokelma |
| Atricure, INC. | $36.78 | 2023 | |
| Janssen Pharmaceuticals, INC | $33.52 | 2024 | Xarelto |
| Cardiva Medical, INC. | $24.88 | 2025 | Cardiva Vascade Mvp Vvcs 6-12f |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Olshan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.